Health Care

U.S. safety regulators have decided not to open a formal investigation into complaints that transmissions can fail in more than 857,000 Nissan trucks.

Toyota is recalling about 5.8 million vehicles in Japan, Europe, China and other countries to replace potentially deadly Takata air bag inflators.

Subaru is recalling more than 100,000 of its top-selling models in the U.S. because a turbocharger air pump can run continuously, overheat and could cause fires.

Privately held drugmaker Kaleo Inc announced on Wednesday plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of next year.

Some good news for the Republican presidential nominee, as a Bloomberg Politics poll shows Trump leading 45% to Clinton’s 43% in the must-win battleground state of Florida.

Award-winning chef Michel Nischan is on a mission to create a sustainable food system for communities in need, and he is now enlisting the help of top executive talent.

Pharmaceutical company GlaxoSmithKline says its net profit rose 50 percent in the third quarter to 808 million pounds ($986 million) thanks in part to strong sales of its vaccine products.

Vertex Pharmaceuticals Inc. on Tuesday reported a loss of $41.8 million in its third quarter.

Chipotle is still struggling to bring back customers to its restaurants after a food safety scare last year.

A must read for American working families...

Merck & Co. (MRK) on Tuesday reported third-quarter net income of $2.18 billion.

Just days before open enrollment begins, the Obama administration announces premiums will jump 22% under the Affordable Care Act in 2017.

Dow component Merck reported an adjusted 3Q profit of $1.07 per share, topping the estimate for $0.99. Revenue for the drugmaker came in at $10.54 billion, also beating the estimate for $10.17 billion

The Obama administration is confirming that premiums will go up sharply next year for health insurance sold to millions of consumers through HealthCare.gov.

Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatment Gilenya.